Aclaris Therapeutics, Inc.

Equities

ACRS

US00461U1051

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 19:37:59 12/07/2024 BST 5-day change 1st Jan Change
1.315 USD +4.37% Intraday chart for Aclaris Therapeutics, Inc. +7.50% +22.86%
LockThis article is reserved for members
To unlock the article, REGISTER!
Already a customer? Log In
Aclaris Therapeutics Insider Bought Shares Worth $405,894, According to a Recent SEC Filing MT
Aclaris Therapeutics Insider Bought Shares Worth $1,742,075, According to a Recent SEC Filing MT
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 2000 Dynamic Index CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell Microcap Growth Index CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 3000E Growth Index CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 3000E Index CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 2500 Growth Index CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell Microcap Value Index CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 3000 Growth Index CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell Small Cap Comp Growth Index CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell Small Cap Completeness Index CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 2000 Growth Index CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 2500 Index CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) added to Russell 3000E Value Index CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 3000 Index CI
Aclaris Therapeutics, Inc.(NasdaqGS:ACRS) dropped from Russell 2000 Index CI
Transcript : Aclaris Therapeutics, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-11-2024 11:20 AM
Transcript : Aclaris Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024
Earnings Flash (ACRS) ACLARIS THERAPEUTICS Reports Q1 Revenue $2.4M, vs. Street Est of $2M MT
Aclaris Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Aclaris Therapeutics, Inc. Announces Board Resignations CI
Aclaris Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Aclaris Therapeutics, Inc. Announces Intangible Asset Impairment for the Three Months Ended December 31, 2023 CI
Earnings Flash (ACRS) ACLARIS THERAPEUTICS Posts Q4 Revenue $17.6M MT
Aclaris Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023 CI
Chart Aclaris Therapeutics, Inc.
More charts
Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases. The Company has a multi-stage portfolio of drug candidates powered by a robust research and development engine exploring protein kinase regulation. Its segments include therapeutics and contract research. The therapeutics segment is focused on identifying and developing therapies to address unmet needs for immuno-inflammatory diseases and providing licensing of its intellectual property. The contract research segment provides laboratory services. The Company's KINect drug discovery platform combined with its preclinical development capabilities allows it to identify and advance potential drug candidates that it may develop independently or in collaboration with third parties. The Company's drug candidates include ATI-1777, ATI-2138 and Zunsemetinib. ATI-1777 is an investigational topical soft Janus kinase, or JAK, 1/3 inhibitor.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
9
Last Close Price
1.26 USD
Average target price
1.84 USD
Spread / Average Target
+46.03%
Consensus